AMZN
Amazon.com, Inc.
AMZN has the edge over CCL overall, supported by stronger modeled upside and stronger valuation.
CCL
Carnival Corporation & plc
CCL offers stronger fundamentals, but that advantage does not outweigh its weaker overall profile.
AMZN Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Weak | |
| Healthy |
AMZN's revenue, profitability and balance sheet are currently healthy, but its cash flow is weak.
CCL Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Under pressure |
CCL's profitability and cash flow are currently healthy, and its revenue is stable, but its balance sheet is under pressure.
AMZN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 22x | $267 | — |
| Forward | 27x | $267 | — |
| Cheap | 34x | $415 | +55% |
| Fair | 60x | $745 | +179% |
| Expensive | 102x | $1,262 | +372% |
Historical ranges are pointers, not guarantees.
AMZN has the edge over CCL in the historical PE scenario, which offers more potential upside but is not a forecast.
CCL PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 10x | $24.05 | -18% |
| Forward | 12x | $29.34 | — |
| Current | 13x | $29.34 | — |
| Fair | 14x | $32.52 | +11% |
| Expensive | 21x | $48.32 | +65% |
Historical ranges are pointers, not guarantees.
CCL's PE is in its fair range at 13x. If earnings grow as analysts expect, today's price would be 12x next year's earnings.
AMZN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Moderate | |
| Moderate |
Analysts expect earnings and revenue growth for AMZN, with profitability improving.
CCL Forward outlook
| Metric | Outlook |
|---|---|
| Stable | |
| Growth | |
| Stable | |
| Improving | |
| Limited | |
| Low |
Analysts expect CCL's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
AMZN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.87 | -20% |
| Q3 2026 | $12.37 | +75% |
| Q2 2026 | $12.43 | +89% |
| Q1 2026 | $8.36 | +36% |
| Q4 2025 | $7.17 | +30% |
| Q3 2025 | $7.08 | +52% |
| Q2 2025 | $6.56 | +57% |
| Q1 2025 | $6.14 | +72% |
| Q4 2024 | $5.53 | +91% |
AMZN's earnings per share have climbed steadily: $12.37 over the past year, up 75% from the year before, and higher year over year for 14 quarters in a row. Its recent earnings include one-off gains.
CCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.39 | +3.3% |
| Q3 2026 | $2.31 | +17% |
| Q2 2026 | $2.24 | +18% |
| Q1 2026 | $2.27 | +46% |
| Q4 2025 | $2.02 | +40% |
| Q3 2025 | $1.97 | +67% |
| Q2 2025 | $1.90 | +168% |
| Q1 2025 | $1.55 | +384% |
| Q4 2024 | $1.44 | +$1.50 |
CCL's earnings per share have fallen from their peak: $2.31 over the past year, against $4.32 in late 2019.
AMZN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $201.9B | +12% |
| Q2 2026 | $200.6B | +20% |
| Q1 2026 | $181.5B | +17% |
| Q4 2025 | $213.4B | +14% |
| Q3 2025 | $180.2B | +13% |
| Q2 2025 | $167.7B | +13% |
| Q1 2025 | $155.7B | +8.6% |
| Q4 2024 | $187.8B | +10% |
AMZN has the edge over CCL on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 14% | +4.2 points |
| Q2 2026 | 14% | +2.3 points |
| Q1 2026 | 13% | +1.3 points |
| Q4 2025 | 12% | +0.4 points |
| Q3 2025 | 9.7% | -1.3 points |
| Q2 2025 | 11% | +1.5 points |
| Q1 2025 | 12% | +1.1 points |
| Q4 2024 | 11% | +3.5 points |
AMZN's operating margin was 14% last quarter, up 4.2 points from the same quarter a year ago, near the top of its range since 2019.
CCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $8.4B | +3.5% |
| Q2 2026 | $6.7B | +5.3% |
| Q1 2026 | $6.2B | +6.1% |
| Q4 2025 | $6.3B | +6.6% |
| Q3 2025 | $8.2B | +3.3% |
| Q2 2025 | $6.3B | +9.5% |
| Q1 2025 | $5.8B | +7.5% |
| Q4 2024 | $5.9B | +10% |
CCL's revenue has grown year over year for 21 quarters in a row: $8.4B last quarter, up 3.5% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 26% | -1.5 points |
| Q2 2026 | 13% | -2 points |
| Q1 2026 | 9.8% | +0.5 points |
| Q4 2025 | 12% | +2.2 points |
| Q3 2025 | 28% | +0.3 points |
| Q2 2025 | 15% | +5.1 points |
| Q1 2025 | 9.3% | +4.2 points |
| Q4 2024 | 9.4% | +2.3 points |
CCL has the edge over AMZN on profitability, with a higher operating margin.
AMZN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$34.8B | -8202% |
| Q2 2026 | -$8.8B | -2757% |
| Q1 2026 | -$18.2B | -$10.2B |
| Q4 2025 | $14.9B | -16% |
| Q3 2025 | $430M | -87% |
| Q2 2025 | $332M | -96% |
| Q1 2025 | -$8B | -297% |
| Q4 2024 | $17.8B | -36% |
AMZN's free cash flow was −$46.9B over the past year, against $10.6B the year before.
CCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $712M | -3.3% |
| Q2 2026 | $1.8B | +14% |
| Q1 2026 | $697M | +119% |
| Q4 2025 | $12M | -96% |
| Q3 2025 | $736M | +17% |
| Q2 2025 | $1.5B | +114% |
| Q1 2025 | $318M | +$688M |
| Q4 2024 | $319M | +29% |
CCL has the edge over AMZN on cash generation, producing positive trailing cash flow while its opponent burns cash.
AMZN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +26M shares |
| 1 year | +0.8% | +84M shares |
| 3 years | +3.5% | +371M shares |
| 5 years | +6.1% | +629M shares |
| Available history | +8.2% | +829M shares |
AMZN has 10.9B diluted shares, up 0.8% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | $3.3B |
CCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.4% | -20M shares |
| 1 year | -2.4% | -34M shares |
| 3 years | -2% | -28M shares |
| 5 years | +21% | +236M shares |
| Available history | +100% | +684M shares |
CCL has the edge over AMZN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $548M |
| Q4 2021 | $94M |
| Q3 2021 | $94M |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
AMZN Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.3x | Very low |
| Q1 2026 | 0.1x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.1x | Net Cash |
| Q2 2025 | -0.0x | Net Cash |
| Q1 2025 | -0.1x | Net Cash |
| Q4 2024 | -0.2x | Net Cash |
AMZN has the edge over CCL on leverage, with a lower net debt burden relative to earnings.
CCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.1x | Elevated |
| Q2 2026 | 3.1x | Elevated |
| Q1 2026 | 3.2x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 3.5x | Elevated |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 4.1x | High |
| Q4 2024 | 4.3x | High |
CCL's net debt is about 3.1 years of its operating earnings (EBITDA), down from 3.5 years a year ago.
AMZN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.1 | Neutral |
| Stochastic | 50.0 | Neutral |
AMZN's weekly RSI is 57 (neutral) and its Stochastic is 50 (neutral).
CCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.6 | Neutral |
| Stochastic | 80.8 | Overbought |
CCL's weekly RSI is 59 (neutral) and its Stochastic is 81 (overbought).
AMZN PE vs Consumer Cyclical Sector
| Metric | AMZN | Sector median | Relative |
|---|---|---|---|
| PE | 22x | 18x | 20% above |
| PE % | 4 | 47 | 43 pts below |
AMZN is trading at 22x earnings, a 20% premium to the Consumer Cyclical sector's median of 18x, though its recent earnings include one-off gains.
CCL PE vs Consumer Cyclical Sector
| Metric | CCL | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 18x | 30% below |
| PE % | 39 | 47 | 8 pts below |
CCL has the edge over AMZN on valuation relative to its sector.
AMZN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $253.6 | 5.5% above |
| 20 week MA | $254.9 | 4.9% above |
| 50 week MA | $242.5 | 10% above |
| 100 week MA | $229.6 | 17% above |
| 200 week MA | $191.4 | 40% above |
AMZN is in an uptrend: it's above all five of its weekly moving averages, and 40% above its 200-week average.
CCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $26.8 | 9.6% above |
| 20 week MA | $26.3 | 12% above |
| 50 week MA | $27.5 | 6.6% above |
| 100 week MA | $26.6 | 11% above |
| 200 week MA | $21.1 | 39% above |
CCL is in an uptrend: it's above all five of its weekly moving averages, and 39% above its 200-week average.
AMZN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $93.5 | $158.6 | +70% |
| 2021 | $158.6 | $171.1 | +7.8% |
| 2022 | $171.1 | $85.3 | -50% |
| 2023 | $85.3 | $151.9 | +78% |
| 2024 | $151.9 | $223.8 | +47% |
| 2025 | $223.8 | $232.5 | +3.9% |
| 2026 YTD | $232.5 | $267.4 | +15% |
AMZN has the edge over CCL on returns for 2026, with the stronger performance.
CCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $51.3 | $20.8 | -59% |
| 2021 | $20.8 | $21.2 | +1.7% |
| 2022 | $21.2 | $7.81 | -63% |
| 2023 | $7.81 | $18.5 | +137% |
| 2024 | $18.5 | $25.1 | +35% |
| 2025 | $25.1 | $30.7 | +22% |
| 2026 YTD | $30.7 | $29.3 | -4.4% |
CCL's yearly returns have swung widely, from +137% in 2023 to −63% in 2022. It's down 4.4% so far in 2026.